Eisai and Biogen Announces That The Therapeutic Goods Administration Of Australia Has Confirmed The Initial Decision To Decline The Approval Of Humanized Anti-Soluble Aggregated Amyloid-Beta Monoclonal Antibody Lecanemab As A Treatment For Early Alzheim